Jason Carroll (researcher) explained

Jason Carroll
Workplaces:Cancer Research UK Cambridge Institute, University of Cambridge
Alma Mater:University of Melbourne
Awards:Fellow of the Academy of Medical Sciences
Spouses:)-->
Partners:)-->

Professor Jason Carroll is a British medical researcher serving as a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge and Founder and Chief Scientific Officer of Azeria Therapeutics.[1] [2] He is a Professor of Molecular Oncology assigned to the Department of Oncology[3] and a Fellow of Clare College, Cambridge.[4]

Education

Carroll completed his B.Sc Hons in Molecular Biology at the University of Melbourne before undertaking his PhD in Cancer Research at The Garvan Institute and University of New South Wales.

Career

Carroll's research uses molecular, genomic and proteomic approaches to understand how the Estrogen Receptor causes gene transcription and how this contributes to breast cancer progression.[5] In 2008, Carroll discovered the molecular mechanism of tamoxifen in breast cancer, demonstrating that tamoxifen switched off the breast cancer gene ErbB2 via the protein Pax2, which acts as a switch. The team showed that tamoxifen resistance occurs when ErbB2 remains on.[6] [7] [8] Carroll also discovered the role of pioneer factor FOXA1 in breast cancer, demonstrating that it is key in enabling the estrogen receptor to interact with the DNA in breast cancer cells, switching on genes that trigger unchecked growth.[9] [10] In 2015, Carroll's work uncovered why women who have high levels of both the estrogen and progesterone receptors have a better chance of breast cancer survival, and found that adding progesterone at the same time as tamoxifen slows tumour growth in the laboratory.[11] [12] [13]

In 2017, Carroll founded Azeria Therapeutics Limited to develop treatments for hormone resistant breast and prostate cancer, building on his work with pioneer factor FOXA1.[2] [14] [15]

Awards and honours

References

  1. Web site: Carroll Group. Cancer Research UK Cambridge Institute. 2019-09-03.
  2. Web site: Azeria Therapeutics Developing pioneering cancer treatments. Azeria Therapeutics. 2019-09-03.
  3. Web site: Institute Group Leaders awarded promotions in the University. 2019-07-24. Cancer Research UK Cambridge Institute. 2019-09-03.
  4. Web site: Fellows of Clare College - Clare College Cambridge. www.clare.cam.ac.uk. 2019-09-03. 2020-08-08. https://web.archive.org/web/20200808193225/http://www.clare.cam.ac.uk/Fellows-of-Clare-College/. dead.
  5. Web site: Jason Carroll - Google Scholar Citations. scholar.google.com. 2019-09-03.
  6. Carroll. Jason S.. Ali. Simak. Howat. William J.. Jiang. Jie. Myles Brown. Nicholson. Robert I.. Hutcheson. Iain R.. Geistlinger. Timothy R.. Holmes. Kelly A.. December 2008. Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen. Nature. 456. 7222. 663–666. 10.1038/nature07483. 19005469. 1476-4687. 2920208. 2008Natur.456..663H .
  7. News: Breast drug failure cause found. 2008-11-13. 2019-09-03.
  8. Web site: Scientists crack the code to tamoxifen resistance. 2008-11-13. University of Cambridge. 2019-09-03.
  9. Carroll. Jason S.. Schmidt. Dominic. Ross-Innes. Caryn S.. Holmes. Kelly A.. Hurtado. Antoni. January 2011. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics. 43. 1. 27–33. 10.1038/ng.730. 21151129. 1546-1718. 3024537.
  10. Web site: Single gene essential for oestrogen response in breast cancer. 2013-12-05. Cancer Research UK. 2019-09-03.
  11. News: Breast cancer hope as hormone shown to slow tumour growth. editor. Ian Sample Science. 2015-07-08. The Guardian. 2019-09-03. 0261-3077.
  12. Web site: Solving a breast cancer mystery – why do 'double-positive' women do better?. Cancer Research UK - Science blog. 8 July 2015 . 2019-09-03.
  13. Carroll. Jason S.. Tilley. Wayne D.. Caldas. Carlos. Stingl. John. Perou. Charles M.. Launchbury. Rosalind. Silva. Grace. Robinson. Jessica L. L.. D’Santos. Clive. July 2015. Progesterone receptor modulates ERα action in breast cancer. Nature. 523. 7560. 313–317. 10.1038/nature14583. 26153859. 1476-4687. 4650274. 2015Natur.523..313M .
  14. Web site: Azeria Therapeutics Business Weekly Technology News Business news Cambridge and the East of England. www.businessweekly.co.uk. 2019-09-03.
  15. Web site: Azeria Therapeutics, the World's First Pioneer Factor Drug Discovery Company, Announces Series A Investment from Sixth Element Capital. Therapeutics. Azeria. www.prnewswire.co.uk. 2019-09-03.
  16. Web site: BACR/AstraZeneca Young Scientist Frank Rose Award BACR - The British Association for Cancer Research. www.bacr.org.uk. 2019-09-03.
  17. Web site: Twenty-one group leaders join network of EMBO Young Investigators. adit. EMBO. 2019-09-03.
  18. Web site: Future Leaders in Cancer Research Prize. 2015-10-28. Cancer Research UK. 2019-09-03.
  19. Web site: Jason Carroll receives AACR Outstanding Investigator Award Scholarship. 2013-09-26. Cancer Research UK Cambridge Institute. 2019-09-03.
  20. Web site: AACR Outstanding Investigator Award for Breast Cancer Research, supported by The Breast Cancer Research Foundation. www.aacr.org. 2019-09-03.
  21. Web site: Louis-Jeantet Young Investigator Career Award Jeantet. admin. 2017-09-17. 2019-09-03.
  22. Web site: Find people in the EMBO Communities. people.embo.org. 2019-09-03.
  23. Web site: The Academy of Medical Sciences announces new Fellows for 2017. 2017-05-08. University of Cambridge. 2019-09-03.
  24. Web site: Dr Jason Carroll The Academy of Medical Sciences. acmedsci.ac.uk. 2019-09-03.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Jason Carroll (researcher)".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.